diphenhydramine hydrochloride has been researched along with af-219 in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 6 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Abdulqawi, R; Dockry, R; Ford, AP; Holt, K; Layton, G; McCarthy, BG; Smith, JA | 1 |
| Green, S; Muccino, D | 1 |
| Brindle, K; Ford, AP; Kitt, MM; Morice, AH; Tershakovec, AM; Thackray-Nocera, S; Thompson, R; Wright, C; Wu, WC | 1 |
| Chung, KF; Song, WJ | 1 |
| Canning, BJ; Dicpinigaitis, PV; McGarvey, LP | 1 |
| Birring, SS; Dabrowska, M; Grabczak, EM; Krenke, R | 1 |
| Slomski, A | 1 |
| Birring, SS; Dicpinigaitis, PV; Green, SA; Iskold, B; La Rosa, C; Li, Q; McGarvey, LP; Morice, AH; Muccino, DR; Nguyen, AM; Pavord, ID; Philip, G; Schelfhout, J; Smith, JA | 1 |
| Irwin, RS; Madison, JM | 1 |
4 review(s) available for diphenhydramine hydrochloride and af-219
| Article | Year |
|---|---|
Update on the clinical development of gefapixant, a P2X3 receptor antagonist for the treatment of refractory chronic cough.
Topics: Animals; Antitussive Agents; Chronic Disease; Cough; Humans; Purinergic P2X Receptor Antagonists; Pyrimidines; Receptors, Purinergic P2X3; Sulfonamides | 2019 |
Pharmacotherapeutic Options for Chronic Refractory Cough.
Topics: Analgesics, Opioid; Antitussive Agents; Chronic Disease; Cough; Gabapentin; Humans; Pyrimidines; Quality of Life; Randomized Controlled Trials as Topic; Sulfonamides | 2020 |
P2X3-Receptor Antagonists as Potential Antitussives: Summary of Current Clinical Trials in Chronic Cough.
Topics: Ageusia; Antitussive Agents; Chronic Disease; Clinical Trials as Topic; Cough; Humans; Imidazoles; Piperidines; Purinergic P2X Receptor Antagonists; Pyridines; Pyrimidines; Receptors, Purinergic P2X3; Sulfonamides | 2020 |
Looking ahead to novel therapies for chronic cough. Part 1 - peripheral sensory nerve targeted treatments.
Topics: Antitussive Agents; Chronic Disease; Cough; Drug Delivery Systems; Humans; Molecular Targeted Therapy; Peripheral Nerves; Pyrimidines; Quality of Life; Sulfonamides; Therapies, Investigational; Treatment Outcome | 2020 |
2 trial(s) available for diphenhydramine hydrochloride and af-219
| Article | Year |
|---|---|
P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study.
Topics: Adult; Aged; Antitussive Agents; Chronic Disease; Circadian Rhythm; Cough; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Purinergic P2X Receptor Antagonists; Pyrimidines; Severity of Illness Index; Sulfonamides; Treatment Outcome; Young Adult | 2015 |
The effect of gefapixant, a P2X3 antagonist, on cough reflex sensitivity: a randomised placebo-controlled study.
Topics: Adult; Aged; Antitussive Agents; Bronchial Provocation Tests; Chronic Disease; Cough; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Purinergic P2X Receptor Antagonists; Pyrimidines; Sulfonamides; United Kingdom; Visual Analog Scale | 2019 |
3 other study(ies) available for diphenhydramine hydrochloride and af-219
| Article | Year |
|---|---|
Gefapixant Curbs Chronic Cough.
Topics: Antitussive Agents; Chronic Disease; Cough; Humans; Pyrimidines; Sulfonamides | 2022 |
Efficacy and Safety of Gefapixant for Refractory or Unexplained Chronic Cough over 52 Weeks.
Topics: Antitussive Agents; Chronic Disease; Cough; Humans; Pyrimidines; Sulfonamides | 2023 |
Gefapixant for Refractory or Unexplained Chronic Cough?
Topics: Antitussive Agents; Chronic Disease; Cough; Humans; Pyrimidines; Sulfonamides | 2023 |